Ren-He Xu studies stem cell development and therapy. He has published near 100 papers with around 10,000 citations and obtained over 10 patents from U.S. and China. The mesenchymal stem cells differentiated from human embryonic stem cells via trophoblasts (T-MSC) his team invented were approved by the U.S. Food and Drug Administration as an investigational new drug for a clinical trial on multiple sclerosis. Currently, Dr. Xu leads a Macau Key R&D project and a China National Key R&D project to promote the clinical application of T-MSC to treat diabetic foot, graft-versus-host disease, and osteoarthritis. Recently his lab demonstrated the developmental potency of T-MSCs via chimerism with the mouse blastocyst.